United States - English - NLM (National Library of Medicine)

lsne, inc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use : while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate injection in women with any of the following conditions: - current or history of thrombosis or thromboembolic disorders - known or suspected breast cancer, other hormone-sens

United States - English - NLM (National Library of Medicine)

cipla usa inc. - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. - hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate in men with "age -related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. - known hypersensitivity to the drug - males with carcinoma of the breast - males with known or suspected carcinoma of the prostate gland - women who are pregnant (see precautions, pregnancy) - patients with serious cardiac, hepatic or renal disease (see warnings) controlled substance testosterone cypionate injection contains testosterone, a schedule iii c

Canada - English - Health Canada

csl behring canada inc - streptokinase - powder for solution - 750000unit - streptokinase 750000unit - thrombolytic agents

Canada - English - Health Canada

csl behring canada inc - streptokinase - powder for solution - 1500000unit - streptokinase 1500000unit - thrombolytic agents

Canada - English - Health Canada

csl behring canada inc - streptokinase - powder for solution - 250000unit - streptokinase 250000unit - thrombolytic agents

Canada - English - Health Canada

glaxosmithkline inc - alitretinoin - capsule - 10mg - alitretinoin 10mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

glaxosmithkline inc - alitretinoin - capsule - 30mg - alitretinoin 30mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

dr. reddy's laboratories inc - alitretinoin - capsule - 10mg - alitretinoin 10mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

dr. reddy's laboratories inc - alitretinoin - capsule - 30mg - alitretinoin 30mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

microbix biosystems inc - urokinase - powder for solution - 250000unit - urokinase 250000unit - thrombolytic agents